US Saves $313bn From Generics And $2.2bn From Biosimilars
AAM’s Annual Report Focuses On Patient & Stakeholder Benefits
The AAM’s 2019 report titled ‘Securing Our Access & Savings’ throws light on the monumental savings and benefits of generics and biosimilars for US patients and other stakeholders. The report urges policymakers to act to address obstacles to the off-patent industry and brings industry’s COVID-19 response in perspective again.
